Navigation Links
Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
Date:8/31/2009

MONT-SAINT-GUIBERT, Belgium, August 31 /PRNewswire/ --

- Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies

Cardio3 BioSciences, today provided an update and review of the clinical development of its unique C-Cure(R) therapy at the European Society of Cardiology Congress in Barcelona. A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure, one of the world's largest unmet medical needs.

The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.

The session was led by Prof. Stephanie Dimmeler (Institute for Cardiovascular Regeneration, Goethe University Frankfurt) and Prof. Michael Tendera (Head, Cardiology Division, Medical University of Silesia, Katowice, Poland) and included cardiology experts from leading European and U.S institutions: Dr Josef Bartunek (Cardiovascular Center Aalst, Belgium), Professors Dominique Charron (St Louis Hospital, Paris, France), Helmut Drexler (Hannover Medical school, Germany), Andre Terzic (Mayo Clinic, Rochester U.S.A) and Catherine Verfaillie (Leuven University, Belgium).

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "The potential of cell therapies for the treatment of heart failure has long been recognised but there have been considerable hurdles to overcome in delivering on the promise. Today's expert pane
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... a recent study in Reproductive BioMedicine Online ... those with an abnormal chromosomal composition can be identified ... blastocysts, thereby classifying the risk of genetic abnormality without ... has undertaken a retrospective study, using their predictive model ...
(Date:5/17/2013)... PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New ... insect pressures , Syngenta unveiled ... celebration today at the company’s RTP Innovation Center. The ... allows company researchers to simulate any agricultural climate and ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... 25 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ... compounds for the treatment of cardiovascular and metabolic disease, ... 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering ... treatment of atherosclerosis. This patent is also pending ...
... -- 3SBio Inc. (Nasdaq:, SSRX ), a ... and marketing biopharmaceutical products, today,announced that it will ... year ended December 31, 2008 after the US ... Following the earnings announcement, 3SBio,s ...
... Feb. 25 Cord Blood America, Inc. (OTC ... cell preservation company ( http://www.cordblood-america.com ) focused on ... to families nationwide and internationally, today announced an ... its current outstanding debt."The restructuring is a major ...
Cached Biology Technology:VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 3VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 43SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cord Blood America Restructures Debt; Projects to be Cash Flow Positive 2
(Date:5/17/2013)... Scientists investigating the interaction of a group of proteins ... damage have identified a new target that could increase ... the University,s School of Biochemistry and published in the ... Reviews, could eventually lead to new therapies for stroke ... earlier work by the team which identified a protein, ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
(Date:5/16/2013)... ancient shorelines to predict the stability of today,s largest ice ... from three million years ago, for example when Earth ... be evidence of a high sea level due to ice ... scientists to think that if the world,s largest ice sheets ... same in our modern, progressively warming world. , However, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New X-ray method shows how frog embryos could help thwart disease 2World's biggest ice sheets likely more stable than previously believed 2
... Texas at San Antonio Assistant Professor of Psychology Rebekah ... from the National Institutes of Health to study adult ... will be recruiting younger adult volunteers aged 18-30 and ... directs the UTSA Cognitive Aging Lab, is studying prospective ...
... A research paper co-written by a Virginia Tech faculty ... nose that is unusually large for its species. The ... journal, Physical Review Letters . The article, ... morphology," by Z. Zhang, R. Mller, and S.N. Truong, ...
... comes to selecting a mating partner: to increase their reproductive ... likely to have more and bigger eggs, as well as ... the Zoological Museum at the University of Zurich in Switzerland. ... Springer,s journal Behavioral Ecology and Sociobiology . Seahorses ...
Cached Biology News:Mystery of bat with an extraordinary nose solved 2Male seahorses like big mates 2
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Biology Products: